natgillin/translations-raw huggingface dataset:
A developer supply container according to claim 3, wherein with increase of a volume of a chamber of the pump portion, the pressure at least in the developer discharging chamber becomes negative. 
Spremnik za nadopunjavanje razvijača u skladu s patentnim zahtjevom 3, naznačen time što s povećavanjem volumena komore navedenog crpnog dijela (2b) tlak u najmanju ruku u navedenoj komori za ispuštanje razvijača (3h) postaje negativan.
An apparatus as claimed in claim 2, wherein the channel is a V shaped conveyor channel wherein one wall of the V is a static wall and the other wall of the V is a conveyor wall. 
Uređaj u skladu s patentnim zahtjevom 2 ili 3, naznačen time što je kanal (4) transportni kanal u obliku slova V, gdje je jedna stijenka profila V je statična stijenka (22), a druga stijenka profila V je transportna stijenka (23).
The composition for use of any preceding claim, wherein the composition comprises a single strain. 
kompozicija obuhvaća jednu vrstu iz roda Blautia; i/ili
A method for improving the adjuvant activity of an imidazoquinoline comprising conjugating the imidazoquinoline to a phospho- or phosphonolipid. 
Postupak poboljšavanja adjuvantne aktivnostu imidazokinolina, naznačen time što se sastoji u konjugiranju imidazokinolina s fosfo- ili fosfonolipidom.
This is advantageous in case the container has to be removed before it is completely emptied. 
To ima prednost u slučaju da se spremnik mora odstraniti prije nego se potpuno isprazni.
Composition which comprises a suspension of red blood cells encapsulating a tumour antigen and an adjuvant for activating dendritic cell maturation, wherein the adjuvant is present in the red blood cells, at their surface and/or outside the red blood cells, for use as a therapeutic anti-tumour vaccine which induces, in a host, a cytotoxic cellular response against tumour cells. 
HR P20171566 T1 PATENTNI ZAHTJEVI Pripravak koji sadrži suspenziju crvenih krvnih stanica koje inkapsuliraju tumorski antigen i adjuvant za aktiviranje starenja dendritske stanice, pri čemu je adjuvant prisutan u crvenim krvnim stanicama, na njihovoj koje inducira, u domaćinu, citotoksični stanični odgovor protiv tumorskih stanica.
Use of the dihydrochloride salt according to claim 1 or 2 for the treatment and/or prophylaxis of a disease selected from a hyper-proliferative and/or angiogenesis disorder, more particularly for the treatment or prophylaxis of a cancer, particularly lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer, hepatocyte carcinoma, pancreatic cancer, hepatocyte carcinoma or breast cancer. 
Uporaba dihidrokloridne soli prema zahtjevu 1 ili 2 naznačena time da je za pripravu medikamenta za liječenje i/ili profilaksu bolesti, naročito hiper-proliferativnog poremećaja 1/ili poremećaja angiogeneze, te naročito za liječenje ili profilaksu raka, naročito raka pluća, osobito raka pluća ne-malih stanica, raka debelog crijeva, melanoma, raka gušterače, karcinoma hepatocita, 1li raka dojke.
Use of a population of metallic nanoparticles to prepare a pharmaceutical composition intended to perturb, alter or destroy target mammalian cells, selected in the group consisting of benign cells, pre-malignant cells and malignant cells, when said cells are exposed to ionizing radiations, wherein the nanoparticles are made of a metal having an atomic number (Z) of at least 25 and the mean largest size of the nanoparticles of the population is between about 80 and 105 nm, and wherein the metallic nanoparticle is covered with a biocompatible coating. 
PATENTNI ZAHTJEVI . Uporaba populacije zlatnih (Au) nanočestica za pripravu farmaceutskog sastava za uporabu u metodi narušavanja, izmjene ili uništavanja ciljnih ljudskih stanica in vivo, odabranih iz grupe koja se sastoji od benignih stanica, premalignih stanica i malignih stanica, pri čemu su navedene stanice izložene ionizirajućim zračenjima, gdje je prosječna najveća veličina nanočestice iz populacije između oko 80 1 105 nm, pri čemu je zlatna nanočestica prekrivena biokompatibilnom oblogom.
melatonin at a concentration of 1.5 to 3% w/v with respect to the final composition, and 
u koncentraciji od 1 do 5% tež./vol. u odnosu na gotovi pripravak i
at least a superficial layer (110), which is intended to be placed on the hole made by the needle, and which is permeable to blood and body exudates; 
- < najmanje jedan površinski sloj (110), koji je namijenjen za postavljanje na otvor načinjen iglom, koji je propustan za krv i tjelesne eksudate;
A computer program product stored on a computer readable storage medium, which when run controls a base station apparatus which transmits, to a mobile station apparatus, a physical downlink control channel, PDCCH, in a search space, to perform the following steps, comprising: transmitting to the mobile station apparatus, in the search space, the PDCCH including a first mobile station identity or a second mobile station identity, wherein the search space is defined based on the first mobile station identity, in a case that the mobile station apparatus has the first mobile station identity and the second mobile station identity; the PDCCH is used for dynamic scheduling when the PDCCH includes the first mobile station identity; and the PDCCH is used for persistent scheduling when the PDCCH includes the second mobile station identity. 
Uređaj bazne stanice koji je prilagođen za odašiljanje, na uređaj mobilne stanice, kontrolnog kanala fizičke silazno veze, PDCCH, u prostoru pretraživanja, naznačen time da uređaj bazne stanice sadrži: sredstva podešena za odašiljanje na uređaj mobilne stanice, u prostoru pretraživanja, te PDCCH sadrži identitet prve mobilne stanice ili identitet druge mobilne stanice, pri čemu je prostor pretraživanja određen na temelju identiteta prve mobilne stanice, u slučaju da uređaj mobilne stanice ima identitet prve mobilne stanice i identitet druge mobilne stanice; PDCCH se koristi za dinamično raspoređivanje kada PDCCH sadrži identitet prve mobilne stanice; a PDCCH se koristi za aktiviranje trajnog raspoređivanja kada PDCCH sadrži identitet druge mobilne stanice.
Concerning their surfaces, the so obtained material, a technical veneer 14, were similar to the typical floor arrangement of a parquet made from oak. 
HR P20070484 T3 S obzirom na svoje površine, tako dobiveni materijal, tehnički furnir 14, bio je sličan tipično složenom parketu koji je načinjen od hrasta.
The compound of the Formula VIII, wherein Lg is halogeno, may be reacted with a compound of the Formula IX in the absence of an acid. 
Spoj prikazan Formulom VIII, u kojoj je Lg halogeno, može se staviti u reakciju sa spojem prikazanim Formulom IX u odsutnosti kiseline.
The process according to claim 1, in which the acid pre-treatment is an acid hydrolysis, acid cooking or steam explosion with prior impregnation of said lignocellulosic substrate with an aqueous sulphuric acid solution. 
Postupak prema jednom od zahtjeva 1 do 3, naznačen time da kisela predobrada je kisela hidroliza, kuhanje s kiselinom ili eksplozija pare s prethodnom impregnacijom navedenog lignoceluloznog supstrata s vodenom otopinom sumporne kiseline.
Transdermal Dosage Forms 
Transdermalni oblici doziranja
The method of claim 1, wherein the first detector is immobilized to a conjugate region of the surface and wherein the conjugate region does not overlap with the test region of the surface. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je prvi detektor imobiliziran na konjugatnom području površine i gdje se konjugatno područje ne preklapa s ispitrvanim područjem površine.
Compounds having such duel effect are also named SNRIs, “serotonin and noradrenaline reuptake inhibitors”, or NSRIs, “noradrenaline and serotonin reuptake inhibitors”. 
Spojeve s takvim dvostrukim učinkom nazivamo I SNRIs "inhibioiri re-apsorpcije serotonina I noradrenalina", ili NSRISs "serotonin ponovne inhibicije"
A thermally insulatingstretchable down feathersheet (10) as claimed in claim 2 wherein each one of said stretchable elastomeric sheets (12,13) is a non-woven lightweight, breathable fibrous web having extension recovery properties. 
Toplinski izolirajućirastezljivi sloj paperja (10) u skladu s patentnim zahtjevom 2, naznačen time što je svaki od navedenih rastezljivih elastomernih slojeva (12,13) netkana laka, prozračna mreža vlakana s odličnim svojstvima oporavka nakon rastezanja.
The method according to claim 1, wherein a host cell is used, which is selected from the group consisting of: 
Imortalizirana stanica iz ljudske krvi, naznačena time što je se bira iz skupine koju čine DSM ACC2858 (GT-2X),
Control of gas composition of a gas separation system having membranes 
KONTROLA PLINSKOG SASTAVA POSTROJENJA ZA ODVAJANJE PLINA S MEMBRANAMA
adding a dry composition mixture to a biological material in a culture medium to form a viscous slurry, wherein the weight mass of the biological material in the culture media is between 5% and 30% w/v, and wherein the added composition mixture in the culture medium is between 10% and 60%, wherein the final solid content in the slurry is from 20% to 60%, wherein the dry composition mixture comprises a disaccharide, an oligosaccharide, a polysaccharide, a hydrolyzed protein, and a carboxylic acid salt; 
(a) dodavanje suhe kompozicije smjese na biološki materijal u medij kulture kako bi se dobila viskozna suspenzija, pri čemu je masa težine biološkog materijala u mediju kulture je između 5% 1 30% w/v, 1 gdje dodana smjesa pripravka u mediju kulture je između 10% 1 60%, pri čemu je konačni sadržaj krute smjese u suspenziji od 20% do 60%, pri čemu smjesa suhe smjese sadrži disaharid, oligosaharid, polisaharid, hidrolizirani protein, i sol karboksilne kiseline;
DB081153.1 (incorporated herein as SEQ ID NO: 7). In certain embodiments, the TMPRSS6 nucleic acid is a modified oligonucleotide. In certain embodiments, TMPRSS6 nucleic acid consists of 12 to 30, 10 to 30, 8 to 80, 10 to 50, 15 to 30, 18 to 21, 20 to 80, 20 to 35, 20 to 30, 20 to 29, 20 to 28, 20 to 27, 20 to 26, 20 to 25, 20 to 24, 20 to 23, 20 to 22, 20 to 21 or 20 linked nucleobases. 
(ii) obuhvaća bar jednu modificiranu internukleozidnu vezu, opcionalno gdje je internukleozidna veza fosforotioatna internukleozidna veza; i/ili (iii) obuhvaća modificirani šećer, opcionalno gdje je modificirani šećer biciklični šećer; i/ili (iv) obuhvaća modificiranu nukleobazu, opcionalno gdje je modificirana nukleobaza 5-metilcitozin; i/ili (vV) se sastoji od 15 do 30, 18 do 21, 20 do 30, 20 do 29, 20 do 28, 20 do 27, 20 do 26, 20 do 25, 20 do 24, 20 do 23, 20 do 22, 20 do 21 ili 20 povezanih nukleobaza.
In some embodiments the isolated antibody is a full-length antibody of an IgG1, IgG2, IgG3, or IgG4 isotype. 
(A) pri čemu navedeno antitijelo je antitijelo pune dužine IgG1, IgG2, 1gG3, ili IgG4 izotipa;
Use according claim 8 or 9 characterised in that the fentanyl is given before administration of CNS 7056, preferably within 10 minutes, more preferably within 5 minutes, and most preferably within 1 or 2 minutes prior to CNS 7056 administration. 
CNS 7056 ili njegova sol ili solvat za primjenu sukladno bilo kojem od prethodnih zahtjeva, naznačen time što se fentanil daje prije davanja CNS 7056, a prvenstveno u roku od 10 minuta, još poželjnije u roku od 5 minuta, i najpoželjnije u roku od 1 ili 2 minuta prije davanja CNS 7056.
a CDRL3 sequence comprising SEQ ID NO.:10 or as set forth in SEQ ID NO.: 10. The antibody or antigen binding fragment thereof of claim 1, wherein the heavy chain variable region is as set forth in SEQ ID NO.:35, SEQ ID NO.:36 or SEQ ID NO.:37 and/or wherein the light chain variable region is as set forth in SEQ ID NO.:30, SEQ ID NO.:31 or SEQ ID NO.:32. 
Humanizirano protutijelo ili njegov fragment koji veže antigen, naznačeno time, da je sposobno za specifično vezanje na antigen 1 povezan s bubregom (KAAGI), pri čemu humanizirano protutijelo ili njegov fragment koji veže antigen posjeduje varijabilno područje teškog lanca koje ima aminokiselinsku sekvencu kako je prikazano u SEQ ID NO:35, SEQ ID NO:36 ili SEQ ID NO:37, te varijabilno područje lakog lanca koje ima aminokiselinsku sekvencu kako je prikazano u SEQ ID NO:30, SEQ ID NO:31 ili SEQ ID NO:32.
citric acid in a proportion comprising between 0.25% and 1.5%; 
- < limunsku kiselinu, u udjelu koji se kreće između 0,25% 1 1,5%;
The compound according to claim 16, or the pharmaceutically acceptable salt thereof or the solvate thereof, wherein R5a is hydrogen, carbocyclic group optionally substituted by substituent group C, carbocycle lower alkyl optionally substituted by substituent group C, heterocyclic group optionally substituted by substituent group C, or heterocycle lower alkyl optionally substituted by substituent group C (wherein substituent group C is same as that of claim 1). 
Spoj prema zahtjevu 16, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat, naznačen time, da R* je vodik, karbociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, karbociklil-niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, heterociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, ili heterocikli-niži alkil prema potrebi supstituiran sa supstituentskom skupinom €, (gdje supstituentska skupina C ima isto značenje kao što je navedeno u zahtjevu 1).
A polypeptide of any of claims 1-3, a polypeptide dimer of claim 4 or claim 5, a fusion protein of claim 6 or claim 7, a fusion protein dimer of any of claims 8-10, a nucleic acid of claim 11, a vector of claim 12, or a cell of claim 13, for use in: 
Polipeptid prema bilo kojem od zahtjeva 1-3, dimerni polipeptid prema zahtjevu 4, fuzijski protein prema zahtjevu 5 ili zahtjevu 6, dimerni fuzijski protein prema zahtjevu 7 ili zahtjevu 8, nukleinska kiselina prema zahtjevu 9, vektor prema zahtjevu 10, ili stanica prema zahtjevu 11, naznačeni time da su za uporabu za:
amplifying the treated DNA by means of 
amplificiranje tretirane DNA pomoću
The chimeric human/non-human animal MHC II polypeptide of any one of claims 11-13, wherein the non-human animal is a mouse, and wherein the human MHC II a polypeptide is selected from the group consisting of HLA-DR a polypeptide, HLA-DQ a polypeptide and HLA-DP a polypeptide, and the non-human animal MHC II a polypeptide is an H-2E a polypeptide; or wherein the human MHC II B polypeptide is selected from the group consisting of HLA-DR B polypeptide, HLA-DQ B polypeptide and HLA-DP B polypeptide, and the non-human animal MHC II B polypeptide is an H-2E B polypeptide. 
Kimerni ljudski/glodarski MHC II-polipeptid prema bilo kojem od patentnih zahtjeva 11 do 13, naznačen time, da glodavac je miš, i pritom je ljudski MHC II-a-polipeptid odabran iz skupine koja se sastoji od HLA-DR-a-polipeptida, HLA-DQ-a-polipeptida i HLA-DP-a-polipeptida, i glodarski MHC II-a-polipeptid je H-2E-a-polipeptid; ili time, da je ljudski MHC II-B-polipeptid odabran iz skupine koja se sastoji od HLA-DR-B-polipeptida, HLA-DQ-B-polipeptida i HLA-DP-B-polipeptida, dok je glodarski MHC II-B-polipeptid jedan H-2E-B-polipeptid.
Ulipristal acetate, or any metabolite thereof, for use in treating or preventing a tumour derived from leiomyomata according to anyone of claims 1 to 11, wherein it is to be administered to said patient before she undergoes surgery of the uterus. 
Ulipristal acetat, ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu se primjenjuje toj bolesnici prije nego što će ići na operaciju maternice.
A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 11, naznačen time što još sadrži farmaceutski prihvatljivu podlogu, razrjeđivač ili pomoćnu tvar.
xanthan gum in a proportion comprised of between 0.2% and 0.5%; 
- < ksantansku gumu, u udjelu koji se kreće između 0,2% 10,5%;
An antibody, or a fragment thereof, which is capable of specific binding to Lymphocyte antigen 75, wherein the antibody or fragment thereof contains or is conjugated to a therapeutic moiety, for use in treatment or prophylaxis of colorectal cancer. 
PATENTNI ZAHTJEVI Žž, Antitijelo koje je sposobno za specifično vezivanje limfocitnog antigena 75 za uporabu u liječenju raka pankreasa pri čemu spomenuto antitijelo sadrži ili se konjugira na terapijski dio.
An expression vector comprising the nucleic acid of claim 20 operably linked to a promoter. A host cell carrying the expression vector of claim 21 . 
Vektor ekspresije, naznačen time, da obuhvaća nukleinsku kiselinu prema zahtjevu 8, koja je radno povezana na pokretač.
having unusually slow rates of progression of disease despite the presence of an established clinical diagnosis of probable Alzheimer's disease. 
(1v) ima neuobičajeno spore brzine napredovanja bolesti usprkos prisutnosti utvrđene kliničke dijagnoze vjerojatne Alzheimerove bolesti.
A method of determining the responsiveness of a human cancer patient to treatment of a cancer disease with an antibody for use of any of claims 1 to 17, said method comprising the step of determining in a sample the blood level of one or more markers in the patient, wherein the one or more markers are selected from the group consisting of CA 125, CA 15-3, CA 19-9, CEA, IL-2, IL-15, IFNY, and TNFa, and a decrease in the level of at least one of the markers following administration of the antibody indicates that the patient is responsive to treatment of a cancer disease, or wherein the marker is IL-6 and an increase in the level of the marker following administration of the antibody indicates that the patient is responsive to treatment of the cancer disease. 
Postupak za određivanje reaktivnosti ljudskog pacijenta s karcinomom čovjeka na liječenje bolesti karcinoma antitijelom za uporabu prema bilo kojem od zahtjeva 1 do 17, naznačen time, da koraka određivanja razine u jednom ili više markera u uzorku u uzorku kod pacijenta, pri čemu su jedan ili više markera odabrani iz skupine koja se sastoji od CA 125, CA 15-3, CA 19-9, CEA, IL-2, IL-15, IFNY i TNFa, i smanjenja udjela razina najmanje jednog od markera nakon primjene antitijela ukazuje da pacijent reagira na liječenje bolesti raka, ili gdje je marker IL-6, a porast razine markera nakon primjene antitijela ukazuje da pacijent reagira na liječenje bolesti raka.
Preferably the size of the engraved features is at least twice the thickness of the carrier. 
Poželjno dimenzija ugraviranih ureza treba biti veća od debljine nosača.
The FTI for use of any one of claims 1 to 13, wherein said method further comprises administering a therapeutically effective amount of a second active agent or a supportive care therapy. 
Spoj za uporabu u skladu s patentnim zahtjevom 1, pri čemu metoda sadrži primjenu terapeutski učinkovite količine druge aktivne tvari ili suportivne terapije.
In particular, a known latch key and latch sub groove combination FINNEGAN includes a latch key having a shaped outer surface that presents a recess having one or more upwardly facing shoulders. 
U posebnom slučaju kombinacija poznate zasuna i šupljine zasuna sadrže zasun koja ima oblikovanu vanjsku površinu koja ima žlijeb, koji ima jedan ili više prema gore usmjerenih ramena.
6, in which it can be noticed that the lower portion thereof is penetrating, from the bottom upwards, the bore 123 in the bottom wall 122 of the box-like base member 110 and, as a result, the bore 156 of the container 151, so that the punch 119 is enabled to reach, inside the serrated cylindrical wall 216, up to a point just below the tip of the cusp 214 of the bottom 202 of the capsule 200 upon its having caused the lower membrane 210 to tear and deform. 
Poluga 114 se zato pokreće iz svoje konfiguracije mirovanje, kao što je ilustrirano gore, u radnu konfiguraciju, prikazanu na Slici 6, gdje se može vidjeti da donji dio prodire s dna prema gore, kroz provrt 123 u podnici 122 kutijastog osnovnog elementa 110, te zbog toga i kroz provrt 156 u spremniku 151, tako da probijač 119 može doseći, unutar nazubljene valjkaste stijenke 216, do točke odmah ispod vrha izbočine 214 na dnu 202 kapsule 200, gdje uzrokuje da se donja membrana 210 razdere i deformira.
wherein the nucleic acid encoding rhodopsin comprises a substitution, insertion or deletion of nucleic acid encoding the miR-708 target sequence, and wherein the miR-708 target sequence is SEQ ID NO:19. 
Čestica rAAV prema patentnom zahtjevu 1, naznačena time što je nukleinska kiselina koja kodira miR-708 i/ili nukleinska kiselina koja kodira rodopsin operativno povezana s promotorom.
The composition of claim 1 or claim 2, wherein the Spy0416 protein antigen is a mutant Spy0416 protein comprising an amino acid alteration at one or more amino acid positions selected from the group consisting of amino acids D151, H279, and S617, wherein the amino acid positions are numbered according to SEQ ID NO:1 and wherein proteolytic activity of the purified mutant Spy0416 antigen against interleukin 8 (IL-8) is reduced by at least 50% relative to wild-type Spy0416 as detected by SDS-polyacrylamide gel electrophoresis or by an ELISA assay. 
Pripravak u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je proteinski antigen iz Spy0416 protein iz mutanta SpyO416 koji ima aminokiselinsku izmjenu na jednom ili više aminokiselinskih položaja koje se bira iz skupine koju čine aminokiseline D151, H279, te S617, gdje su aminokiselinski položaji numerirani prema SEQ ID NO:1, te gdje je proteolitička aktivnost pročišćenog antigena iz mutanta Spy0416 protiv interleukina 8 (IL-8) smanjena za najmanje 50% u odnosu na divlji tip Spy0416, što je uočeno elektroforezom na
A combination for use according to claim 9 wherein the disorder mediated by inappropriate PI3-kinase activity is asthma. 
Kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 11, naznačena time što je poremećaj uzrokovan neodgovarajućom aktivnošću P13-kinaze astma.
Use of claim 8, wherein the disorder or the disease is selected from hyperlipidemia, arteriosclerosis, atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, cardiovascular disorder, coronary heart disease, coronary artery disease, coronary vascular disease, angina, ischemia, heart ischemia, thrombosis, cardiac infarction such as myocardial infarction, stroke, peripheral vascular disease, reperfusion injury, angioplasty restenosis, hypertension, congestive heart failure, diabetes such as type II diabetes mellitus, diabetic vascular complications, obesity or endotoxemia etc. 
hiperkolesterolemija, = hipertrigliceridemija, = porodična - hiperkolesterolemija, kardiovaskularni poremećaj, koronarna srčana bolest, koronarna arterijska bolest, koronarna vaskularna bolest, angina, ishemija, srčana ishemija, tromboza, kardijski infarkt kao primjerice miokardijski infarkt, udar, periferalna vaskularna bolest, reperfuzijska ozljeda, angioplastična Testinoza, hipertenzija, kongestivni srčani zastoj, dijabetes kao primjerice dijabetes melitus tipa II, dijabetske vaskularne komplikacije, pretilost ili endotoksemija.
formoterol, or a salt thereof or a solvate of said salt, at a dosage in the range of from 1 to 25 µg per actuation; 
(b) formoterol, ili njegovu sol ili solvat rečene soli, u dozi u rasponu od 1 do 25 ug po aktiviranju;
In some preferred embodiments, the IL-23 antagonist is an antibody or antibody fragment that binds to and inhibits the activity of either IL-23p19 or IL-23R. 
IL-17 antagonist za uporabu u skladu sa zahtjevom 8, naznačen time, da se monoklonsko antitijelo ili fragment monoklonskog antitijela veže na i inhibira djelovanje IL-17.
The synthesis method according to claim 1, wherein the enzymatic hydrolysis reaction is carried out by use of the esterase obtained from strain AJ3 of Ophiostoma novo-ulmi. 
Postupak sinteze u skladu s patentnim zahtjevom 1, naznačen time, da se reakcija enzimske hidrolize provodi upotrebom esteraze dobivene iz soja AJ3 Ophiostoma novo-u/mi.